Low Leverage / Zero DebtZero reported debt materially reduces refinancing and interest-rate risk, giving the company greater financial flexibility to fund R&D and commercialization. A debt-free structure supports resilience during cash burn phases and preserves optionality for strategic partnerships or targeted investments.

Recent Revenue RecoveryA 22% revenue increase in 2025 indicates improving commercial traction and demand for the platform. Sustained top-line growth, if continued, supports scale economics and validates product-market fit in target segments, improving prospects for durable margin and cash-flow improvement.

Product-Market Fit In Growing End MarketsThe acoustofluidic AcouWash addresses core processing needs (washing, separation, buffer exchange) in expanding cell therapy and bioprocessing markets. Structural growth in cell therapies and lab automation can sustain demand for label-free microfluidic solutions, supporting long-term commercial opportunity.

Bears Say

Persistent Operating LossesMulti-year net losses indicate the core business is not yet profitable, prolonging dependence on external financing. Persistent operating deficits constrain reinvestment capacity, increase dilution risk from future raises, and make achieving sustainable profitability a multi-quarter to multi-year challenge.

Weak Cash GenerationConsistently negative operating and free cash flow undermines self-funding ability and heightens funding risk. Without reliable cash generation, the company faces recurring capital raises or partnerships to support operations, which can dilute shareholders and limit long-term strategic autonomy.

Margin Sustainability / Cost PressureA sharply negative gross margin in 2025 and recurring EBIT/EBITDA losses point to cost structure or pricing challenges. Persistent negative margins question scalability: unless unit economics improve, revenue growth may not translate into durable profitability or positive free cash flow.

ACOU FAQ

What was AcouSort AB’s price range in the past 12 months?

AcouSort AB lowest stock price was kr2.03 and its highest was kr7.28 in the past 12 months.

What is AcouSort AB’s market cap?

AcouSort AB’s market cap is kr48.04M.

When is AcouSort AB’s upcoming earnings report date?

AcouSort AB’s upcoming earnings report date is May 27, 2026 which is in 83 days.

How were AcouSort AB’s earnings last quarter?

AcouSort AB released its earnings results on Feb 25, 2026. The company reported -kr0.12 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.12.

Is AcouSort AB overvalued?

According to Wall Street analysts AcouSort AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AcouSort AB pay dividends?

AcouSort AB does not currently pay dividends.

What is AcouSort AB’s EPS estimate?

AcouSort AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AcouSort AB have?

AcouSort AB has 21,163,902 shares outstanding.

What happened to AcouSort AB’s price movement after its last earnings report?

AcouSort AB reported an EPS of -kr0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.775%.

Which hedge fund is a major shareholder of AcouSort AB?

Currently, no hedge funds are holding shares in SE:ACOU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AcouSort AB

AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.